| Lestaurtanib(CEP-701) [12, 13] |
1 |
Relapsed or refractory AML w FLT3 mutation |
Nausea vomiting, fatigue |
5/14 (1CRi) |
| Midostaurin(PKC412) [14, 15] |
IIb |
Relapsed or refractory AML w or w/o FLT3 mutation |
Nausea vomiting |
32/57(1PR) |
| Sunitinib (SU11248) [16, 17] |
I |
Relapsed refractory AML w or w/o FLT3 mutation |
Fatigue, hypertension, heart failure |
7/16(1CRi) |
| Tandutinib (MLN518) [18, 19] |
I |
Relapsed refractory AML w or w/o FLT3 mutation |
Muscle weakness, fatigue |
2/8(2 blast reductions) |
| Sorafenib(Bay 43-9006) [20] |
I |
Relapsed refractory AML w or w/o FLT3 mutation |
Elevated transaminases, Musculoskeletal pain |
11/15(11 SD) |
| KW-2449 [21, 22] |
I |
Relapsed refractory AML w or w/o FLT3 mutation |
Nausea, vomiting fatigue |
1/6(1blast reduction) |
| Quizartinib(AC220) [23, 24] |
II |
Relapsed or refractory AML with FLT3 ITD mut |
QTc prolongation |
44/99(44CRc) |
| Crenolanib[25] |
I |
Relapsed refractory AML w or w/o FLT3 mutation |
TBD |
Ongoing |
| Ponatinib[26] |
I |
Relapsed refractory AML w or w/o FLT3 mutation |
Pancreatitis |
3/12(2CRi) |
